SABS (SAB Biotherapeutics) Marketable Securities: $86.87 Mil (As of Mar. 2026)


SABS SAB Biotherapeutics Inc SABS
34 GF Score
Price $3.81
! 2 Warning Signs
View Full Analysis

What is SAB Biotherapeutics Marketable Securities?

SAB Biotherapeutics SABS -3.78% 34 Marketable Securities is $86.87 Mil as of Mar. 2026. GuruFocus rates SABS with a GF Score™ of 34/100. The stock has 2 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. SAB Biotherapeutics's Marketable Securities for the quarter that ended in Mar. 2026 was $86.87 Mil.

SAB Biotherapeutics's annual Marketable Securities increased from Dec. 2023 ($0.00 Mil) to Dec. 2024 ($11.86 Mil) and increased from Dec. 2024 ($11.86 Mil) to Dec. 2025 ($86.09 Mil).

SAB Biotherapeutics  (NAS:SABS) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

SAB Biotherapeutics Marketable Securities Related Terms

SAB Biotherapeutics Marketable Securities Historical Data

* Premium members only.

The historical data trend for SAB Biotherapeutics's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

SAB Biotherapeutics Marketable Securities Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial 0.00 0.00 0.00 11.86 86.09

SAB Biotherapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.21 2.02 81.46 86.09 86.87
SABS
34GF Score
SAB Biotherapeutics Inc SABS
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

SAB Biotherapeutics Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of $86.87 Mil mean?
SAB Biotherapeutics (SABS) has a Marketable Securities of $86.87 Mil as of Mar. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on SAB Biotherapeutics and its competitors.
Is SAB Biotherapeutics' Marketable Securities too high?
SAB Biotherapeutics' current Marketable Securities is $86.87 Mil. Overall, SAB Biotherapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does SAB Biotherapeutics' Marketable Securities compare to SRZN and GLSI?
SAB Biotherapeutics' Marketable Securities of $86.87 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on SAB Biotherapeutics and its competitors. SAB Biotherapeutics's current Marketable Securities is $86.87 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SAB Biotherapeutics stock overvalued right now?
SAB Biotherapeutics (SABS) has a current Marketable Securities of $86.87 Mil. The current Marketable Securities is $86.87 Mil. SAB Biotherapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For SAB Biotherapeutics (SABS), the current Marketable Securities is $86.87 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

SAB Biotherapeutics Business Description

Address 777 West 41st Street, Suite 401, Miami Beach, FL, USA, 33140
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.
34GF Score

Get the complete analysis for SABS

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.81
Price